In today’s rapidly evolving environment, drug and device companies face new challenges to deliver better patient outcomes at lower costs. KPMG is a leading advisor to the Life Sciences industry, providing a wide range of services to help organizations grow their business, enhance performance, and manage risks.
We offer a market-leading portfolio of methodologies, tools and services to assist Life Science companies in the following areas:
Independent audit and assurance services
Analyses and assessments on R&D effectiveness
Transactions (due diligence, integration and separation)
Tax compliance and governance
Value chain analysis
Risk management and regulatory compliance
Disruptive technologies and advanced analytics
Contact
KPMG Basel
Viaduktstrasse 42
PO Box 3456
4002 Basel
Tel. +41 58 249 91 91
Fax +41 58 249 91 23
KPMG Life Sciences Team Switzerland: https://home.kpmg.com/ch/en/home/industries/life-sciences.html
Patient-driven drug pricing, the uncertain future of Switzerland’s tax regime, and new business models for life science innovators in a changing global market are just a few of the topics…
Europe accounts for a substantial share of Takeda’s business, hosts a significant slice of the company’s manufacturing footprint, and is involved in around half of its late-stage trials and priority…
Genmab is moving into one of the most consequential chapters in its history, as decades of antibody innovation converge with an ambition to take greater ownership of the journey from…
The debate around Europe’s pharmaceutical future is shifting beyond innovation alone towards the broader challenge of sustaining access, strengthening resilience and creating a more competitive operating environment. Arun Narayan outlines…
The priority should be to ensure that reimbursement systems can support sustainable healthcare budgets, timely patient access and continued pharmaceutical innovation Delivering the first approved treatment for metabolic dysfunction-associated steatohepatitis…
The European Commission has set itself an ambitious target: making Europe the world’s most attractive destination for life sciences by 2030. In recent conversations with PharmaBoardroom, executives leading Europe for…
The opportunity now is to ensure that the policy and access environment evolves at the same pace as the science Europe possesses one of the world’s strongest scientific ecosystems, yet…
Europe’s position as a global healthcare leader is being tested by intensifying competition from both the US and China. As CSL’s Dirk Hoheisel points out, this is not because Europe…
Whilst G7 countries have long been the traditional homes of pharmaceutical innovation, there is increased global competition, and a real risk that this longstanding leadership will be lost without concerted…
Nearly six years after becoming a standalone business, Merz Therapeutics is expanding beyond its neurotoxin heritage to build a broader specialty neurology platform across Europe and internationally. Newly appointed Region…
Europe stands at a critical moment as healthcare systems face growing pressure to accelerate patient access, adapt to more complex therapies, and remain competitive in a global innovation race increasingly…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share…
Natural remedies are on the rise. The USD 80 billion global natural health products market is projected to nearly double by 2033, according to Market Growth Reports, as patients with…
See our Cookie Privacy Policy Here
